FDA approves new treatment for certain advanced or metastatic breast cancers
The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient ’s hormones (endocrine therapy).
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Food and Drug Administration (FDA) | HER2 | Hormones